Interferon beta-1b has been shown to possess both antiviral and immunoregulatory activity. The mechanisms by which interferon beta-1b exerts its actions in multiple sclerosis are not clearly understood. However, it is known that the biological response-modifying properties of interferon beta-1b are mediated through its interactions with specific cell receptors found on the surface of human cells.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L03AB08 | Interferon beta-1b | L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AB Interferons |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| EXTAVIA Powder and solvent for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Interferon beta-1b is an active ingredient of these brands:
Australia (AU)
Austria (AT)
Finland (FI)
Hong Kong (HK)
Israel (IL)
Japan (JP)
Lithuania (LT)Netherlands (NL)
New Zealand (NZ)
Romania (RO)
Singapore (SG)
South Africa (ZA)
Tunisia (TN)
United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
